Canaccord Genuity Maintains Buy on 2seventy bio, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst John Newman maintains a Buy rating on 2seventy bio (NASDAQ:TSVT) but lowers the price target from $12 to $11.
May 09, 2024 | 7:08 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity maintains a Buy rating on 2seventy bio but lowers the price target from $12 to $11.
The reduction in price target by Canaccord Genuity could have a mixed impact on TSVT's stock price. While maintaining a Buy rating indicates a positive outlook on the stock, the lowered price target might signal a tempered expectation for its short-term growth potential. Investors might react cautiously to the adjusted price target, balancing the positive Buy rating against the reduced target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100